Keywords: |
treatment response; cancer surgery; gene mutation; cancer risk; note; cancer staging; clinical practice; colorectal cancer; homologous recombination; cancer susceptibility; cancer immunotherapy; incidence; morbidity; genetic variability; risk factor; colorectal neoplasms; acetylsalicylic acid; colonoscopy; colorectal tumor; family history; clinical decision making; epithelial cell adhesion molecule; awareness; rectum cancer; lynch syndrome; protein msh6; colorectal neoplasms, hereditary nonpolyposis; mismatch repair protein pms2; technology; hereditary nonpolyposis colorectal cancer; colectomy; disease surveillance; clinical outcome; colon, sigmoid; sigmoid; cancer prognosis; humans; human; mutl protein homolog 1; dna mismatch repair protein msh2; checkpoint inhibitor therapy
|